Systemic Lupus Erythematosus (SLE) is a life-threatening autoimmune disease characterized by adaptive immune system activation, formation of double-stranded DNA autoantibodies and organ inflammation. SLE is a prototypic systemic autoimmune disease with a prevalence of 0.1% in the general population predominantly affecting young women. In SLE, immune tolerance against nuclear antigens including double-stranded (ds) DNA and nuclear proteins is broken, leading to the emergence of autoantibodies against dsDNA, and other nuclear antigens, which subsequently trigger immune complex-induced inflammation in an array of different organs, such as the kidneys, the heart, the lungs and the skin.
Now in a World 1st, Five patients with SLE (four women and one man) with a median age of 22 years, median disease duration of 4 years has been treated with one-time Anti CD19 CAR-T cell therapy and the disease has been sent to remission with no relapse.
The treatment, known as Chimeric Antigen Receptor (CAR) T-cell therapy has been used in Cancer treatment, and is dramatically transforming the field of cancer immunotherapy.
The antiCD19 CAR-T cell therapy in B cell malignancies was first reported in 2010, the field has increased considerably and immuno-oncology researchers are working to apply this cellular therapy to various types of cancers including solid tumors.
This is a great breakthrough says, Dr. Georg Schett, director of rheumatology and immunology at Friedrich Alexander University Erlangen-Nuremberg in Germany. Just a single shot of CAR T cells and patients can stop all treatments. More larger cohort studies are planned in the future. Hopeful good news for moderte to severe SLE sufferers.
Now in a World 1st, Five patients with SLE (four women and one man) with a median age of 22 years, median disease duration of 4 years has been treated with one-time Anti CD19 CAR-T cell therapy and the disease has been sent to remission with no relapse.
The treatment, known as Chimeric Antigen Receptor (CAR) T-cell therapy has been used in Cancer treatment, and is dramatically transforming the field of cancer immunotherapy.
The antiCD19 CAR-T cell therapy in B cell malignancies was first reported in 2010, the field has increased considerably and immuno-oncology researchers are working to apply this cellular therapy to various types of cancers including solid tumors.
This is a great breakthrough says, Dr. Georg Schett, director of rheumatology and immunology at Friedrich Alexander University Erlangen-Nuremberg in Germany. Just a single shot of CAR T cells and patients can stop all treatments. More larger cohort studies are planned in the future. Hopeful good news for moderte to severe SLE sufferers.
